earnings
confidence high
sentiment neutral
materiality 0.75
Harrow Q1 revenue up 33% to $34.6M; net loss widens; FY2024 guidance at least $180M
HARROW, INC.
2024-Q1 EPS reported
-$0.38
revenue$34,587,000
- Q1 revenue $34.6M (+33% YoY); GAAP net loss $(13.6M) vs $(6.6M) prior year; adj. EBITDA $0.2M vs $5.3M.
- Reaffirms FY2024 revenue guidance of at least $180M, expecting growth with back half stronger.
- VEVYE covered lives exceed 150M (from 40M); IHEEZO CMS separate reimbursement confirmed retroactive to Jan 1, 2024.
- Signed IHEEZO supply agreements with 7 multi-practice accounts; new patent through 2039. TRIESENCE PPQ batch passing preliminary assays.
- Appointed Greg DiPasquale as SVP, Head of Commercial (from Regeneron). Sold Eton shares for $5.5M cash.